Publications by authors named "P Zeitler"
Context: 47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be attributable to inadequate testosterone during the mini-puberty period of infancy.
Objective: We tested the hypothesis that exogenous testosterone treatment positively effects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY.
Youth-onset type 2 diabetes is a heterogeneous disease with increasing prevalence in relation to increased rates of obesity in children. It has genetic, epigenetic, social, and environmental determinants. Youth-onset type 2 diabetes is alarming given a rapidly progressive course compared with the course of adult-onset disease, early-onset vascular complications, and long-term exposure to hyperglycemia and associated complications.
View Article and Find Full Text PDFObjective: To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo.
Research Design And Methods: Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.
Results: Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.
Background: 1.8% of youth identify as transgender; a growing proportion are transgender male (female sex, male gender identity). Many receive gonadotropin releasing hormone agonist (GnRHa) therapy to suppress endogenous puberty and/or will start testosterone to induce secondary sex characteristics that align with gender identity.
View Article and Find Full Text PDFArticle Synopsis
- This study examined the baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and assessed how the medication tirzepatide influenced their glycemic control, body weight, and cardiometabolic health.
- It compared 3,792 participants with early-onset T2D to those with later-onset, revealing that early-onset individuals were generally younger, had longer diabetes durations, and exhibited worse metabolic health indicators at the start.
- After 40 weeks of treatment with tirzepatide, both groups showed similar improvements in key health metrics like HbA1c, body weight, waist circumference, and lipid levels, indicating the drug's effectiveness across different onset ages.